Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 20/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | STS | P08842 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Letrozole SCHEMBL4331 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL178028 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL29079510 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL5326636 | 0.89 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL1026263 | 0.87 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL28081077 | 0.87 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL10323873 | 0.82 | CYP19A1 (0.54) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL13285157 | 0.82 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL5430341 | 0.82 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL10075551 | 0.82 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150524-B2 | Pure intermediate | GENERICS [UK] LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20140378420-A1 | METHODS FOR THE TREATMENT OF BREAST CANCER | SYNDAX PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | MERCK SHARP & DOHME CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130203826-A1 | Pure Intermediate | GENERICS [UK] LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8470297-B1 | FDG-pet evaluation of Ewing's sarcoma sensitivity | MERCK SHARP & DOHME CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | disclosed |
| US-20120058112-A1 | ANTIBODIES | MERCK SHARP & DOHME CORP. | 2012-03-08 | — | — | US | disclosed |
| US-8124614-B2 | Steroidal compounds for inhibiting steroid sulphatase | STERIX LIMITED (GB) | 2012-02-28 | — | — | US | disclosed |
| US-7459565-B2 | Regiospecific process for the preparation of 4-[1- (4-cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl] benzonitrile | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-12-02 | — | — | US | disclosed |
| US-20080112888-A1 | IGFBP2 BIOMARKER | SCHERING CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-20080090242-A1 | PANEL OF BIOMARKERS FOR PREDICTION OF FTI EFFICACY | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-7276513-B2 | Steroidal compounds for inhibiting steroid sulphatase | STERIX, LTD. (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112202-A1 | Letrozole production process | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070105886-A1 | Steroidal compounds for inhibiting steroid sulphatase | RICHTER GEDEON NYRT. (HU) | 2007-05-10 | — | — | US | disclosed |
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | DR. REDDY'S LABORATORIES, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070066831-A1 | Process for the preparation of letrozole | SICOR, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070054899-A1 | Aromatase inhibitor compounds and uses thereof | PARALLEL WIRELESS, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | CYP19A1, CYP2C19, CYP17A1 | CYP19A1 1/4885CYP3A4 4/4885CYP11B1 80/4885 |
| US-20150168424-A1 | IGFBP2 Biomarker | IGFBP2, IGFBP1, IGFBP5 | CYP19A1 379/4885CYP3A4 3596/4885CYP11B1 2865/4885 |
| US-20130243692-A1 | FDG-PET EVALUATION OF EWING'S SARCOMA SENSITIVITY | IGF1R, IRS1, EWSR1 | CYP19A1 400/4885CYP3A4 2778/4885CYP11B1 3953/4885 |
| US-20080112888-A1 | IGFBP2 BIOMARKER | IGFBP2, IGFBP1, IGFBP5 | CYP19A1 379/4885CYP3A4 3596/4885CYP11B1 2865/4885 |
| US-20070066831-A1 | Process for the preparation of letrozole | CYP19A1, CYP4B1, CYP3A4 | CYP19A1 1/4885CYP3A4 3/4885CYP11B1 14/4885 |
| US-20070105886-A1 | Steroidal compounds for inhibiting steroid sulphatase | STS, NR5A1, CYP21A2 | CYP19A1 37/4885CYP3A4 358/4885CYP11B1 34/4885 |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CYP19A1, HSD17B11, SHBG | CYP19A1 1/4885CYP3A4 6/4885CYP11B1 27/4885 |
| US-20130203826-A1 | Pure Intermediate | CYP19A1, CYP11A1, CYP11B1 | CYP19A1 1/4885CYP3A4 9/4885CYP11B1 3/4885 |
| US-20120058112-A1 | ANTIBODIES | IGF1R, EGFR, ERBB3 | CYP19A1 1082/4885CYP3A4 4577/4885CYP11B1 4672/4885 |
| US-20070054899-A1 | Aromatase inhibitor compounds and uses thereof | CYP19A1, CYP17A1, HSD17B11 | CYP19A1 1/4885CYP3A4 41/4885CYP11B1 5/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | CYP19A1 489/4885CYP3A4 3752/4885CYP11B1 802/4885 |
| US-20070112202-A1 | Letrozole production process | CYP19A1, CDK14, CDK19 | CYP19A1 1/4885CYP3A4 5/4885CYP11B1 26/4885 |
| US-20140378420-A1 | METHODS FOR THE TREATMENT OF BREAST CANCER | CYP19A1, HDAC1, HSD17B11 | CYP19A1 1/4885CYP3A4 343/4885CYP11B1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.